J&J PhC leads Aquinox $18m C round
This article was originally published in Scrip
Executive Summary
Aquinox Pharmaceuticals has raised US $18 million in a Series C venture capital financing, enabling it to conduct two more Phase II trials of its lead product, the anti-inflammatory AQX-1125. Aquinox has attracted the interest of phenture capitalists: both Pfizer’s and J&J’s corporate funds participated in earlier rounds and the Johnson & Johnson Development Corporation led this latest round. Intriguingly, given Europe’s latest financial meltdown, they are joined in the latest round by Augment Investments, the Cyprus-incorporated majority shareholder of Russian pharmaceutical company, OJSC Pharmstandard.